Intramedullary Spinal Cord Metastasis (ISCM) Arising from Small Cell Lung Cancer (SCLC)

2010 ◽  
Vol 45 (1) ◽  
pp. 78
Author(s):  
Sang-Bum Kim ◽  
Byung-Hak Oh ◽  
Seong-Kwon Cho ◽  
Cheol-Mog Hwang ◽  
Youn-Moo Heo ◽  
...  
2005 ◽  
Vol 42 (5) ◽  
pp. 567-570 ◽  
Author(s):  
Aki Kato ◽  
Hitoshi Katayama ◽  
Hironobu Hamada ◽  
Tomoaki Nagao ◽  
Toru Kadowaki ◽  
...  

2002 ◽  
Vol 52 (6) ◽  
pp. 627
Author(s):  
Sang Woo Park ◽  
Hyung Soo Wi ◽  
Hoon Soo Kim ◽  
Jae Hwa Cho ◽  
Hong Lyeol Lee ◽  
...  

2013 ◽  
Vol 79 (3-4) ◽  
Author(s):  
S. Katsenos ◽  
M. Nikolopoulou

Intramedullary thoracic spinal metastasis from small-cell lung cancer. S. Katsenos, M. Nikolopoulou. Lung cancer with intramedullary spinal cord metastasis (ISCM) is a rare event exhibiting dismal prognosis. In the present paper, we describe a 74-year-old male who developed bilateral leg weakness with associated backache and non-productive cough. Chest imaging evaluation demonstrated pronounced bilateral mediastinal lymphadenopathy and a nodular opacity in the right lower lobe. The patient was diagnosed with small cell lung cancer through bronchoscopic procedures. Magnetic resonance imaging of the spinal cord with contrast-enhancement revealed an intramedullary lesion consistent with metastasis at the T5-T6 level. Despite chemotherapy and thoracic spine radiotherapy, he eventually succumbed to the disease 3 months after diagnosis. A brief overview of the current literature is also provided laying emphasis on the therapeutic strategies of this unusual extrathoracic metastatic disease.


2008 ◽  
Vol 18 (1) ◽  
pp. 54-56
Author(s):  
Meftun Unsal ◽  
Cengiz Cokluk ◽  
Hande Turker

Haigan ◽  
1997 ◽  
Vol 37 (6) ◽  
pp. 899-902 ◽  
Author(s):  
Ikuma Kasuga ◽  
Masayuki Kikawada ◽  
Akira Kunisawa ◽  
Yasushi Torii ◽  
Yuichi Ichinose ◽  
...  

2014 ◽  
Vol 9 (8) ◽  
pp. e60-e61
Author(s):  
Kristin N. Arreola ◽  
James Ying ◽  
Randall Hughes ◽  
David E. Gerber ◽  
D.W. Nathan Kim

2006 ◽  
Vol 17 (5) ◽  
pp. 372-374 ◽  
Author(s):  
Georgios Koutsis ◽  
Konstantinos Spengos ◽  
Constantin Potagas ◽  
Antonios Dimitrakopoulos ◽  
Konstantinos Sfagos ◽  
...  

2006 ◽  
Vol 24 (1) ◽  
pp. 46-49 ◽  
Author(s):  
Maria Nikolaou ◽  
Maria Koumpou ◽  
Nicolaos Mylonakis ◽  
Athanasios Karabelis ◽  
Dimitris Pectasides ◽  
...  

2021 ◽  
Author(s):  
Huanbing Lu ◽  
Jinfeng Liu ◽  
Chenglong Sun ◽  
Zhanggu Wang

Abstract Purpose Spinal cord intramedullary metastasis (ISCM) is a rare malignant tumor of the nervous system. Small cell lung cancer (SCLC) accounts for about 15% of lung cancer, and the incidence of brain metastasis is high, but intramedullary spinal cord metastasis is rare. In recent years, the first-line treatment of patients with ISCM from SCLC has been controversial. For these patients with ISCM, the options are usually depending on the progression of the disease.However,the outcom of treatments are not satisfacted.Thus,We try to indentify the use of immunotherapy in ISCM from SCLC. Methods In our review, we focused on clinical trials of immunotherapy, especially in relation to ISCM in SCLC. Results A patient was diagnosed as ISCM from SCLC. Radiotherapy for ISCM was started on January 11, 2021 Apatinib was taken orally after radiotherapy. The overall survival was almost 8 months, and there was only 1 month after ISCM was diagnosed. Conclusion Finding practical treatment options for SCLC is an important goal. Previous trials have shown that immunotherapy with checkpoint inhibitors may be an effective approach for long-term disease control and a new breakthrough in the treatment of ISCM form SCLC.


Sign in / Sign up

Export Citation Format

Share Document